Paratek Pharmaceuticals Revenue vs. Cash And Equivalents
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
For Paratek Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Paratek Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Paratek Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Paratek Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Paratek Pharmaceuticals over time as well as its relative position and ranking within its peers.
Paratek |
Paratek Pharmaceuticals Cash And Equivalents vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Paratek Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Paratek Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Paratek Pharmaceuticals is rated top company in revenue category among its peers. It is rated below average in cash and equivalents category among its peers creating about 0.38 of Cash And Equivalents per Revenue. The ratio of Revenue to Cash And Equivalents for Paratek Pharmaceuticals is roughly 2.64 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Paratek Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Paratek Revenue vs. Competition
Paratek Pharmaceuticals is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 280.96 Million. Paratek Pharmaceuticals totals roughly 150.79 Million in revenue claiming about 54% of equities under Health Care industry.
Paratek Cash And Equivalents vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Paratek Pharmaceuticals |
| = | 150.79 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Paratek Pharmaceuticals |
| = | 57.01 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Paratek Cash And Equivalents Comparison
Paratek Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Paratek Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Paratek Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Paratek Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Paratek Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Paratek Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.
Paratek Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Paratek Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Paratek Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Paratek Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Paratek Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Use Investing Themes to Complement your Paratek Pharmaceuticals position
In addition to having Paratek Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Junk Bonds Funds Thematic Idea Now
Junk Bonds Funds
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |